StockNews.com began coverage on shares of Evoke Pharma (NASDAQ:EVOK – Free Report) in a research report report published on Monday. The firm issued a sell rating on the specialty pharmaceutical company’s stock.
Evoke Pharma Stock Performance
EVOK stock opened at $5.84 on Monday. The firm has a 50-day simple moving average of $4.99 and a two-hundred day simple moving average of $5.52. Evoke Pharma has a one year low of $3.54 and a one year high of $17.88. The firm has a market cap of $4.78 million, a price-to-earnings ratio of -0.36 and a beta of 0.36.
Evoke Pharma (NASDAQ:EVOK – Get Free Report) last issued its quarterly earnings results on Tuesday, August 13th. The specialty pharmaceutical company reported ($0.93) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.72) by ($0.21). The business had revenue of $2.55 million for the quarter. Evoke Pharma had a negative return on equity of 964.25% and a negative net margin of 86.74%.
Evoke Pharma Company Profile
Evoke Pharma, Inc, a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It offers Gimoti, a metoclopramide nasal spray to treat symptoms associated with acute and recurrent diabetic gastroparesis in adults.
Read More
- Five stocks we like better than Evoke Pharma
- Canadian Penny Stocks: Can They Make You Rich?
- What a Trump Win Looks Like for the Market Now and Into 2025
- Do Real Estate Investment Trusts Deserve a Place in Your Portfolio?
- Russell 2000 Surge Post-Election: How to Play the Small-Cap Pop
- What is Put Option Volume?
- Macro Headwinds Send Microchip Technology Stock to the Buy Zone
Receive News & Ratings for Evoke Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evoke Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
